Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $89 and keeps an Outperform rating on the shares following the Q2 report. The firm says the company will release the Phase 2b data for aleniglipron by the end of 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
- Structure Therapeutics files automatic mixed securities shelf
- Structure Therapeutics initiated with a Buy at Clear Street
- Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs